Loading...
XSTO
SENZA
Market cap20mUSD
Dec 05, Last price  
6.60SEK
1D
7.49%
1Q
12.63%
IPO
-83.42%
Name

SenzaGen AB

Chart & Performance

D1W1MN
XSTO:SENZA chart
P/E
P/S
3.38
EPS
Div Yield, %
Shrs. gr., 5y
11.03%
Rev. gr., 5y
84.16%
Revenues
58m
+15.69%
1,624,0001,748,000498,0001,153,0001,997,0002,724,0007,958,00015,422,00041,770,00049,870,00057,695,000
Net income
-18m
L-19.22%
262,000-2,857,000-8,942,000-12,994,000-16,090,000-50,237,000-27,315,000-31,346,000-24,912,000-22,097,000-17,850,000
CFO
-9m
L-43.29%
1,042,999-6,281,000-9,692,000-11,646,000-23,212,000-31,081,000-29,376,000-20,980,000-16,071,000-16,453,000-9,330,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
IPO date
Sep 21, 2017
Employees
35
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT